Wall Street brokerages predict that Albireo (NASDAQ:ALBO) will report $55.33 million in sales for the current fiscal quarter, Zacks Investment Research reports. Three analysts have made estimates for Albireo’s earnings, with the highest sales estimate coming in at $56.00 million and the lowest estimate coming in at $55.00 million. The firm is scheduled to issue its next quarterly earnings report on Monday, January 1st.
On average, analysts expect that Albireo will report full year sales of $42.91 million for the current financial year, with estimates ranging from $5.65 million to $56.00 million. For the next year, analysts anticipate that the business will post sales of $12.92 million per share. Zacks’ sales calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for Albireo.
Albireo (NASDAQ:ALBO) last issued its quarterly earnings results on Thursday, March 15th. The biopharmaceutical company reported ($0.55) EPS for the quarter, topping analysts’ consensus estimates of ($0.78) by $0.23.
Several research firms recently issued reports on ALBO. Zacks Investment Research lowered shares of Albireo from a “buy” rating to a “hold” rating in a report on Wednesday, January 17th. BidaskClub upgraded shares of Albireo from a “hold” rating to a “buy” rating in a report on Tuesday, March 20th. Wedbush restated a “buy” rating on shares of Albireo in a report on Wednesday, January 3rd. Needham & Company LLC began coverage on shares of Albireo in a report on Thursday, March 15th. They issued a “buy” rating and a $50.00 target price on the stock. Finally, Jefferies Group began coverage on shares of Albireo in a report on Friday. They issued a “buy” rating and a $50.00 target price on the stock. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $57.60.
In related news, major shareholder Life Sciences Maste Perceptive purchased 275,000 shares of the firm’s stock in a transaction on Thursday, January 25th. The stock was purchased at an average cost of $33.00 per share, with a total value of $9,075,000.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Phase4 Partners Ltd sold 100,000 shares of Albireo stock in a transaction on Tuesday, January 30th. The shares were sold at an average price of $34.44, for a total transaction of $3,444,000.00. The disclosure for this sale can be found here. Insiders own 22.30% of the company’s stock.
Institutional investors and hedge funds have recently bought and sold shares of the business. Perceptive Advisors LLC increased its position in shares of Albireo by 56.2% during the fourth quarter. Perceptive Advisors LLC now owns 1,320,000 shares of the biopharmaceutical company’s stock worth $33,792,000 after acquiring an additional 475,000 shares in the last quarter. Artal Group S.A. bought a new stake in shares of Albireo during the fourth quarter worth about $7,680,000. Sectoral Asset Management Inc increased its position in shares of Albireo by 53.6% during the fourth quarter. Sectoral Asset Management Inc now owns 242,803 shares of the biopharmaceutical company’s stock worth $6,216,000 after acquiring an additional 84,776 shares in the last quarter. Millennium Management LLC increased its position in shares of Albireo by 65.4% during the fourth quarter. Millennium Management LLC now owns 46,594 shares of the biopharmaceutical company’s stock worth $1,193,000 after acquiring an additional 18,425 shares in the last quarter. Finally, Ardsley Advisory Partners bought a new stake in shares of Albireo during the fourth quarter worth about $289,000. 26.88% of the stock is owned by hedge funds and other institutional investors.
ALBO stock traded down $1.05 during midday trading on Friday, hitting $31.93. The stock had a trading volume of 7,864 shares, compared to its average volume of 70,702. The firm has a market cap of $395.82, a price-to-earnings ratio of -10.47 and a beta of 1.60. Albireo has a 1-year low of $15.31 and a 1-year high of $39.87.
ILLEGAL ACTIVITY NOTICE: “$55.33 Million in Sales Expected for Albireo (ALBO) This Quarter” was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this news story on another site, it was stolen and reposted in violation of US and international copyright and trademark laws. The original version of this news story can be viewed at https://www.dispatchtribunal.com/2018/04/24/55-33-million-in-sales-expected-for-albireo-albo-this-quarter.html.
Albireo Pharma, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal (GI) disorders in the United States. Its lead product candidate includes A4250, an orally administered ileal sodium dependent bile acid transporter (IBAT) inhibitor that is in phase II clinical trial for treating progressive familial intrahepatic cholestasis and primary biliary cholangitis.
Get a free copy of the Zacks research report on Albireo (ALBO)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Albireo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albireo and related companies with MarketBeat.com's FREE daily email newsletter.